The treatment of DCs with GA at a concentration of 100 μg/ml suppressed IL-17 and IFN-γ production in healthy subjects (Fig 5B and 5D), but had no effect in MS patients (Fig 5A and 5C). This evidence concerns the gene IL17A and myeloid sarcoma.